Abstract

Research Article

Pharmaco-economic study and cost of care for chronic diseases: Case of Haemophilia in Morocco

Khairoun C*, Khorassani M, Kili A, Hssissen L, Kababri M and Khattab M

Published: 02 April, 2020 | Volume 3 - Issue 1 | Pages: 024-026

This paper is an attempt to enrich the literature about the role that can play some economic approaches, such as cost-effectiveness analysis, in order to help medical stuffs to decide about the treatment to adopt in case of a chronic disease such as Haemophilia. Data from morocco were gathered in order to explain the importance of such approaches.

Read Full Article HTML DOI: 10.29328/journal.japch.1001013 Cite this Article Read Full Article PDF

Keywords:

Pharmaco-economic study; Cost-effectiveness analysis; Haemophilia; Prophylaxis

References

  1. Ministry of Health. National Chronic Disease Plan 2007-2011 [Internet]. 2007.
  2. World Health Organization. WHO: Chronic diseases.
  3. Carrier S, Morin P, Gross O, De La Tribonnière X. L'engagement de la personne dans les soins de santé et services sociaux: Regards croisés France-Québec: Presses de l'Université du Québec. 2017.
  4. https://www.mloz.be/sites/default/files/publications/envol_cout_maladies_chroniques_0318.pdf
  5. Hemophilia B in Morocco. Current state and outlook.
  6. Emmanuil Kombarelis, willim P. J Clini Epidemiology. 2011; 47.
  7. Hay CR, Brown S, Collins PW. le diagnosticet la gestion du facteur VII et IX,Centre d'hémophilie Br, Haematol. 2006; 133: 591-605.
  8. Jenny Goudemand, Yves Laurien. 'hémophilie Orphanet Mai. 2006.
  9. Kessler CM, Goldman L. Hemmoragic disorders :coagulation factor diferences,cecil Medecine 23rd ed,Philadelphia, Sauders Elsevier. 2007; 180.
  10. Kessler CM, Mariani. manifestations cliniques et traitement de l'hémophilie,Hemostasis et Thrombosis 5èd Philadelphia. 2006; 887.
  11. Khachidz M, Buil A, Viel KR, Porter S. Genetic determinants of normal variation in coagulation factor IX. Hemostasis Thrombosis. 2006; 4: 1537-1545.
  12. Siegmund B, Richter H, Pollmann H. Need for prophylactic treatment in adult haemophilia A patients. Transfusion Medicine and Hemotherapy. 2009; 36: 283-288.
  13. Suzuki Katsuhiko. Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules. 2019; 9: 223. PubMed: https://pubmed.ncbi.nlm.nih.gov/31181700/
  14. Cortesi, Paolo Angelo, Gianluca Trifirò, Simona Serao Creazzola, Giovanni Improta, et al. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. Thromb Haemost. 120.02 (2020): 216-228. PubMed: https://pubmed.ncbi.nlm.nih.gov/31887777/
  15. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996; 92: 973-978. PubMed: https://pubmed.ncbi.nlm.nih.gov/8616096/
  16. Matsumura Risa. Pharmacokinetics of Extended Half-Life Factor VIII Products By my PKFiTR Is Useful for Personalized Treatment in Children with Severe Hemophilia a. 2019; 1127.

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More